181 related articles for article (PubMed ID: 8599208)
1. Bicistronic and two-gene retroviral vectors for using MDR1 as a selectable marker and a therapeutic gene.
Metz MZ; Matsumoto L; Winters KA; Doroshow JH; Kane SE
Virology; 1996 Mar; 217(1):230-41. PubMed ID: 8599208
[TBL] [Abstract][Full Text] [Related]
2. Harvey murine sarcoma virus/MDR1 retroviral vectors: efficient virus production and foreign gene transduction using MDR1 as a selectable marker.
Metz MZ; Best DM; Kane SE
Virology; 1995 Apr; 208(2):634-43. PubMed ID: 7747435
[TBL] [Abstract][Full Text] [Related]
3. MDR1 bicistronic vectors: analysis of selection stringency, amplified gene expression, and vector stability in cell lines.
Kane SE; Matsumoto L; Metz MZ; Donohue CA; Lingeman RG; Lin SW; Doroshow JH
Biochem Pharmacol; 2001 Sep; 62(6):693-704. PubMed ID: 11551514
[TBL] [Abstract][Full Text] [Related]
4. Expression of the human multidrug resistance and glucocerebrosidase cDNAs from adeno-associated vectors: efficient promoter activity of AAV sequences and in vivo delivery via liposomes.
Baudard M; Flotte TR; Aran JM; Thierry AR; Pastan I; Pang MG; Kearns WG; Gottesman MM
Hum Gene Ther; 1996 Jul; 7(11):1309-22. PubMed ID: 8818718
[TBL] [Abstract][Full Text] [Related]
5. Poor expression of MDR1 transgene in HeLa cells by bicistronic Moloney murine leukemia virus-based vector.
Zaboikin MM; Schuening FG
Hum Gene Ther; 1998 Oct; 9(15):2263-75. PubMed ID: 9794210
[TBL] [Abstract][Full Text] [Related]
6. Transduction of NIH 3T3 cells with a retrovirus carrying both human MDR1 and glutathione S-transferase pi produces broad-range multidrug resistance.
Doroshow JH; Metz MZ; Matsumoto L; Winters KA; Sakai M; Muramatsu M; Kane SE
Cancer Res; 1995 Sep; 55(18):4073-8. PubMed ID: 7664283
[TBL] [Abstract][Full Text] [Related]
7. In vivo drug-selectable markers in gene therapy.
Sugimoto Y; Tsuruo T
Leukemia; 1997 Apr; 11 Suppl 3():552-6. PubMed ID: 9209454
[TBL] [Abstract][Full Text] [Related]
8. Retroviral coexpression of a multidrug resistance gene (MDR1) and human alpha-galactosidase A for gene therapy of Fabry disease.
Sugimoto Y; Aksentijevich I; Murray GJ; Brady RO; Pastan I; Gottesman MM
Hum Gene Ther; 1995 Jul; 6(7):905-15. PubMed ID: 7578409
[TBL] [Abstract][Full Text] [Related]
9. Construction and characterization of bicistronic retroviral vectors encoding the multidrug transporter and beta-galactosidase or green fluorescent protein.
Aran JM; Gottesman MM; Pastan I
Cancer Gene Ther; 1998; 5(4):195-206. PubMed ID: 9694071
[TBL] [Abstract][Full Text] [Related]
10. A bicistronic retrovirus vector containing a picornavirus internal ribosome entry site allows for correction of X-linked CGD by selection for MDR1 expression.
Sokolic RA; Sekhsaria S; Sugimoto Y; Whiting-Theobald N; Linton GF; Li F; Gottesman MM; Malech HL
Blood; 1996 Jan; 87(1):42-50. PubMed ID: 8547675
[TBL] [Abstract][Full Text] [Related]
11. Selection of transduced CD34+ progenitors and enzymatic correction of cells from Gaucher patients, with bicistronic vectors.
Migita M; Medin JA; Pawliuk R; Jacobson S; Nagle JW; Anderson S; Amiri M; Humphries RK; Karlsson S
Proc Natl Acad Sci U S A; 1995 Dec; 92(26):12075-9. PubMed ID: 8618847
[TBL] [Abstract][Full Text] [Related]
12. Efficient expression of drug-selectable genes in retroviral vectors under control of an internal ribosome entry site.
Sugimoto Y; Aksentijevich I; Gottesman MM; Pastan I
Biotechnology (N Y); 1994 Jul; 12(7):694-8. PubMed ID: 7764914
[TBL] [Abstract][Full Text] [Related]
13. Drug-selected co-expression of P-glycoprotein and gp91 in vivo from an MDR1-bicistronic retrovirus vector Ha-MDR-IRES-gp91.
Sugimoto Y; Tsukahara S; Sato S; Suzuki M; Nunoi H; Malech HL; Gottesman MM; Tsuruo T
J Gene Med; 2003 May; 5(5):366-76. PubMed ID: 12731085
[TBL] [Abstract][Full Text] [Related]
14. Efficient long-term coexpression of a hammerhead ribozyme targeted to the U5 region of HIV-1 LTR by linkage to the multidrug-resistance gene.
Lee CG; Jeang KT; Martin MA; Pastan I; Gottesman MM
Antisense Nucleic Acid Drug Dev; 1997 Oct; 7(5):511-22. PubMed ID: 9361910
[TBL] [Abstract][Full Text] [Related]
15. Construction and characterization of single-transcript tricistronic retroviral vectors using two internal ribosome entry sites.
Metz MZ; Pichler A; Kuchler K; Kane SE
Somat Cell Mol Genet; 1998 Jan; 24(1):53-69. PubMed ID: 9776981
[TBL] [Abstract][Full Text] [Related]
16. The selectable marker neo gene down-regulates gene expression from retroviral vectors containing an internal ribosome entry site.
Byun J; Kim JM; Robbins PD; Kim S
Gene Ther; 1998 Oct; 5(10):1441-4. PubMed ID: 9930351
[TBL] [Abstract][Full Text] [Related]
17. Retroviral vectors containing chimeric promoter/enhancer elements exhibit cell-type-specific gene expression.
Couture LA; Mullen CA; Morgan RA
Hum Gene Ther; 1994 Jun; 5(6):667-77. PubMed ID: 7948129
[TBL] [Abstract][Full Text] [Related]
18. Improved retroviral vectors for hematopoietic stem cell protection and in vivo selection.
Baum C; Eckert HG; Stockschläder M; Just U; Hegewisch-Becker S; Hildinger M; Uhde A; John J; Ostertag W
J Hematother; 1996 Aug; 5(4):323-9. PubMed ID: 8877707
[TBL] [Abstract][Full Text] [Related]
19. Efficient transduction of human hematopoietic cells with the human multidrug resistance gene 1 via SV40 pseudovirions.
Rund D; Dagan M; Dalyot-Herman N; Kimchi-Sarfaty C; Schoenlein PV; Gottesman MM; Oppenheim A
Hum Gene Ther; 1998 Mar; 9(5):649-57. PubMed ID: 9551613
[TBL] [Abstract][Full Text] [Related]
20. Generation of a conditionally neo(r)-containing retroviral producer cell line: effects of neo(r) on retroviral titer and transgene expression.
Wildner O; Candotti F; Krecko EG; Xanthopoulos KG; Ramsey WJ; Blaese RM
Gene Ther; 1998 May; 5(5):684-91. PubMed ID: 9797874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
